Below are the HCPCS codes to use for third party payer billing of INTERCEPT platelet and plasma provided in the hospital outpatient treatment setting:

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Long Descriptor</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>P9070</td>
<td>Plasma, pooled multiple donor, pathogen reduced, frozen, each unit</td>
<td>1/1/2016</td>
</tr>
<tr>
<td>P9071</td>
<td>Plasma (single donor), pathogen reduced, frozen, each unit</td>
<td>1/1/2016</td>
</tr>
<tr>
<td>P9073</td>
<td>Platelets, pheresis, pathogen reduced, each unit</td>
<td>1/1/2018</td>
</tr>
</tbody>
</table>

Effective 1/1/2018, HCPCS P9073 replaces HCPCS Q9988 to bill pathogen reduced apheresis platelets. HCPCS Q9988 is inactive effective 1/1/2018.

Standard billing practices apply to transfusion procedures used to administer pathogen reduced, psoralen-treated INTERCEPT platelet and plasma products administered in the outpatient treatment setting.

Standard billing practices apply to INTERCEPT platelet and plasma products administered in the hospital inpatient treatment setting.

---

**About INTERCEPT**

Pathogen reduced apheresis platelet components prepared using the INTERCEPT Blood System for Platelets ("INTERCEPT platelets," "psoralen-treated platelets") are intended to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and to potentially reduce the risk of transfusion-associated graft-versus-host disease (TA-GVHD).

Pathogen reduced whole blood derived or apheresis plasma components prepared using the INTERCEPT Blood System for Plasma ("INTERCEPT plasma," "psoralen-treated plasma") are intended to reduce the risk of TTI.

For questions about the INTERCEPT Blood System, contact Cerus Corporation by phone (855) 835-3523 or visit www.interceptusa.com.

---

**References:**
The INTERCEPT Blood System for Platelets and Plasma package inserts: [http://intercept-usa.com/resources](http://intercept-usa.com/resources)

Hospital Outpatient Prospective Payment – Final Rule with Comment Period and Final CY2018 Payment Rates: [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1678-FC.html](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1678-FC.html)

The information provided here is for informational purposes only and may be subject to change. Always check with individual third party payers to verify their requirements for billing these products and associated transfusion services.
INTENDED USES

The INTERCEPT Blood System for platelets is intended to be used for ex vivo preparation of pathogen-reduced Amicus apheresis platelet components suspended in 65% PAS-3/35% plasma, and Trima apheresis platelet components suspended in 100% plasma in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD).

The INTERCEPT Blood System for plasma is intended to be used for ex vivo preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of TTI.

CONTRAINDICATIONS

Contraindicated for preparation of platelet components or plasma intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of platelet components or plasma intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

PLATELETS

Pulmonary events: Acute Respiratory Distress Syndrome (ARDS)

INTERCEPT processed platelets may cause the following adverse reaction: Acute Respiratory Distress Syndrome (ARDS)

An increased incidence of ARDS was reported in a randomized trial for recipients of INTERCEPT processed platelets, 5/318 (1.6%), compared to recipients of conventional platelet components (0/327). Monitor patients for signs and symptoms of ARDS.

PLASMA

Amotosalen-treated plasma may cause the following adverse reaction: Cardiac Events

In a randomized controlled trial of therapeutic plasma exchange (TPE) for TTP, five patients treated with INTERCEPT Blood System processed plasma and none with conventional plasma had adverse events in the cardiac system organ class (SOC) reported. These events included angina pectoris (n=3), cardiac arrest (n=1), bradycardia (n=1), tachycardia (n=1) and sinus arrhythmia (n=1). None of these events resulted in documented myocardial infarction or death. Monitor patients for signs and symptoms of cardiac events during TPE for TTP.

Rx Only. See package inserts for full prescribing information.